Posted by Michael Wonder on 27 Jan 2023
Recommendations made by the PBAC – December 2022 intracycle meeting
27 January 2023 - Recommendations made by the PBAC in December 2022 relating to the listing of drugs on the PBS are now available.
It wasn't a good day for AstraZeneca.
The following medicines were rejected:
- Acalabrutinib (Calquence) - AstraZeneca (new medicine)
- Ibrutinib (Imbruvica) - Janssen (new indication)
- Tixagevimab and cilgavimab (Evusheld) - AstraZeneca (new combination product)
On the brighter side of life, the PBAC recommended
- Human papilloma virus vaccine (9 valent) (Gardasil 9) - restriction change
- Migalastat hydrochloride (Galafold) - new (LSDP) medicine
The submission from AstraZeneca for trastuzumab deruxtecan (Enhertu) for patients with breast cancer was deferred.
